Siga Technologies Inc. · NASDAQ:SIGA
Siga Technologies — Q4 2025 Earnings Presentation
20 slides from Siga Technologies's earnings presentation, Mar 10, 2026
Slide 1: Company Overview
Company Overview A Leader in Global Health & Infectious Diseases
Slide 2: Forward Looking Statements
Forward Looking Statements 2
Slide 3: Contents
Contents 1 Introduction 2 The Smallpox Threat 3 TPOXX®: A Differentiated Product 4 Financial Summary
Slide 4: SIGA at a Glance
SIGA at a Glance We are dedicated to advancing our strategic initiatives, driving shareholder value, and enhancing national health security as we deliver TPOXX to U.S. and global government agencies and progress our clinical programs. - Diem Nguyen, Chief Executive Officer Who We Are SIGA is a publi
Slide 5: SIGA is a Leader in Global Health Security
SIGA is a Leader in Global Health Security Fully Integrated Infectious Disease Capabilities Foundation for Continued Attractive Growth • Commercial stage pharmaceutical company operating within • Opportunities for TPOXX expansion (post-exposure prophylaxis infectious disease and health security ”PEP
Slide 6: Executing on our Strategy for Growth
Executing on our Strategy for Growth COMPETITIVE STRATEGIC KEY TRENDS RESULTING IN ADVANTAGE PRIORITIES Greater awareness of the Government contracting Continue our partnership Strong Financial need for preparedness in and relations with the U.S. Government Performance the event of an outbreak Suppl
Slide 7: Comprehensive Capabilities Provide Strong Foundation
Comprehensive Capabilities Provide Strong Foundation Deep Proven R&D capabilities Government Development Close coordination with government agencies to jointly Long-standing relationships Contracting Expertise develop high-impact therapies with key government agencies Experience More than a decade o
Slide 8: Experienced Leadership in Infectious Diseases and Government Relations
Experienced Leadership in Infectious Diseases and Government Relations Diem Nguyen, PhD, MBA Dan Luckshire Chief Executive Officer Chief Financial Officer Larry Miller Dennis Hruby General Counsel Chief Scientific Officer 8
Slide 9: Strong, Durable Financial Performance Over Time
Strong, Durable Financial Performance Over Time SIGA is Well Product Revenues ($mm) Pre-tax Operating Income ($mm) Positioned Financially $127 $131 $133 $85 $89 $84 Company maintains a $116 $70 strong balance sheet $87 $88 $43 through disciplined $24 cash management and no debt 2020 2021 2022 2023 2
Slide 10: The Smallpox Threat
The Smallpox Threat
Slide 11: Smallpox: Historic Milestones
Smallpox: Historic Milestones Highly contagious and fatal disease in susceptible population 2017 2018 2021 2022 2024 2024 Canadian researchers U.S. FDA Health Canada EMA and MHRA (UK) U.S. Bipartisan Commission Japan’s PDMA approves synthesize horsepox, a approves approves approve Tecovirimat- on Bi
Slide 12: Smallpox Remains a Significant Threat Today
Smallpox Remains a Significant Threat Today Current geopolitical environment heightens the need for vigilance More than Smallpox can spread The ongoing geopolitical Smallpox globally before issues and advancements continues to 30% The Growing pose a serious global threat. Historic 300M symptoms appe
Slide 13: TPOXX: A Differentiated Product
TPOXX: A Differentiated Product
Slide 14: TPOXX at a Glance
TPOXX at a Glance A highly targeted antiviral treatment against orthopoxviruses, including smallpox As the first FDA-approved antiviral treatment for smallpox, TPOXX was among the first therapies delivered to the U.S. SNS under Project BioShield. TPOXX’s was developed in partnership with, and with f
Slide 15: TPOXX is a Clinically Differentiated Medical Countermeasure
TPOXX is a Clinically Differentiated Medical Countermeasure Antivirals Vaccines TPOXX ACAM2000® TEMBEXA® IMVANEX/IMVAMUNE/ Tecovirimat SIGA, TEPOXX (plus other replicating (CMX001/brincidofovir) JYNNEOS® (MVA-BN®) (ST-246/tecovirimat) vaccinia vaccine) ▪ First FDA-approved drug with ▪ FDA-approved d
Slide 16: Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX
Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX 2011 TPOXX CONTRACT 2018 TPOXX CONTRACT Procurement Duration 2011-2018 2018-current Key Agency Involved U.S. Biomedical Advanced Research U.S. Biomedical Advanced Research and Development Authority (BARDA) and
Slide 17: TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox
TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox Antiviral Post-Exposure Prophylaxis Antiviral Treatment (Developing Label Expansion) (FDA Approved) VACCINE (HEALTH SECURITY GAP) TPOXX INCUBATION (ASYMPTOMATIC STAGE) FEVER RASH DAY 1 DAY 4 DAY 14 DAY 17 DAY 20 INFECTION INFECTIOUS S
Slide 18: Financial Summary
Financial Summary
Slide 19: Strong Financial Performance
Strong Financial Performance ($ in millions) 2020 2021 2022 2023 2024 2025 Product Revenues 1 U.S. Government Orders under Current Contracts Oral TPOXX $113 $113 $7 $110 $84 $53 (U.S. Government) ▪ ~$546 mm of TPOXX ordered for SNS ▪ ~$30 mm of oral TPOXX ordered by the Department Oral TPOXX $2 $13
Slide 20: Key Takeaways
Key Takeaways Leveraging Building on Driving Organic Expanding Delivering Robust Infectious Disease Successful Growth Platform with Financial Foundation TPOXX Franchise Initiatives Inorganic Growth Performance Leading health security Proven track record of Multiple organic growth Attractive opportun